Results 121 to 130 of about 1,181 (167)

From Markup to Value: Global Implications of Iran's Cost-plus Pharmaceutical Pricing for Emerging Markets. [PDF]

J Res Pharm Pract
Hayat H.
europepmc   +1 more source

[Cost aspects and reimbursement requirements of phage therapy]. [PDF]

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
Häckl D, Dillschneider J, Elsner C.
europepmc   +1 more source

Results of health technology assessments of orphan drugs in Germany-lack of added benefit, evidence gaps, and persisting unmet medical needs. [PDF]

Int J Technol Assess Health Care
Kranz P, McGauran N, Ünal C, Kaiser T.
europepmc   +1 more source

[Digital health applications-What we should know as rheumatologists]. [PDF]

Z Rheumatol
Knitza J, Krusche M, Chehab G, Specker C, Richter JG.   +4 more
europepmc   +1 more source

Effect of nurse-led medication reviews - an interventional study [PDF]

, 2013
Lisby, Marianne, Mainz, Jan, Nielsen, Lars Peter, Poulsen, Birgitte Klindt, Sørensen, Ann Lykkegaard   +4 more
core  

The impacts of pricing and reimbursement policies on access to cell and gene therapies across Europe. [PDF]

J Community Genet
Han Y, Andreoletti M, Minssen T, Vayena E, Ormond KE.   +4 more
europepmc   +1 more source

Pharmaindustrie in Deutschland: Positive Entwicklung in 2015

, 2016
Kirchhoff, Jasmina
core  

Disease Interception im AMNOG-Verfahren

openaire   +1 more source